{"id":898925,"date":"2025-10-22T10:10:54","date_gmt":"2025-10-22T14:10:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/"},"modified":"2025-10-22T10:10:54","modified_gmt":"2025-10-22T14:10:54","slug":"nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/","title":{"rendered":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) &#8212; Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting.<\/p>\n<p>Nkarta will present clinical data showing that the company\u2019s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates across multiple tissues. These data highlight NKX019\u2019s potential as a novel therapeutic approach for B-cell driven autoimmune diseases.<\/p>\n<p>Our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_sNo4ljbESYpiFfaoYAkJbwo7vIdueCmnGXfiqQG-2aFxXXs9gSyUTW-jC_IEOSWupauhPrVwxrALisNKHRHroSzFOhFmpvkcJdIHhJ7T2Ok-vg_PkjTgEeer8EUYVPm0N22900yD0gXkY5H9ts7rhVO5ypAwIBcZlBqQP8S7y71w8dxI03ow32eiwB7JnS3YUy3tv2XdoHxGwehFvGSbUlPy2PG6Ha1JJPgbjRGE68Qh0KyHY413wxYfsYI0G_VcfkIZJcjhzUJ2D3MsSsH2pVzg06nb7QiBBmzwSNTgfl14k8QJeGl9a_1Of514VP48Cs77OCFUMAtZzwTmPvNbQ==\" rel=\"nofollow\" target=\"_blank\">accepted abstract<\/a> can be accessed on the ACR Convergence 2025 website.\u00a0<\/p>\n<p>\u201cMillions of patients in the United States are living with autoimmune diseases driven by pathological B cells, and current treatment paradigms are often inadequate or limited by toxicities, leaving patients with few options,\u201d said Mira Tohm\u00e9, PhD, associate director of translational research at Nkarta, who will present the poster. \u201cOur data highlight the potential for our engineered, allogeneic NK cells to treat a range of autoimmune diseases by selectively depleting the disease-driving B cells without inducing limiting toxicities.\u201d<\/p>\n<p>Details of the Sunday poster presentation are as follows:<\/p>\n<p>\n        <strong>Abstract Title:<\/strong> NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease<br \/><strong>Presenting Author<\/strong>:\u00a0Mira Tohm\u00e9 (ID: 2762863)<br \/><strong>Date:<\/strong> Sunday, October 26<br \/><strong>Presentation Time:<\/strong> 10:30 AM &#8211; 12:30 PM CT<br \/><strong>Room:\u00a0<\/strong>Hall F1<br \/><strong>Session: (0001\u20130018) <\/strong>B Cell Biology &amp; Targets in Autoimmune &amp; Inflammatory Disease Poster I<br \/><strong>Submission Number:<\/strong> 2130624<br \/><strong>Poster Number:\u00a0<\/strong>0014<\/p>\n<p>In addition to the poster presentation, Nkarta will exhibit at booth #1801, where attendees can meet with Nkarta representatives to discuss the company\u2019s clinical programs.<\/p>\n<p>\n        <strong>About Nkarta<\/strong><br \/>\n        <br \/>Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h2aMe0L1bl1fe4_BoVPs82_4qkycVYPRp2bQSMFFcuWVt3z0XqAAohp6nFOQWSdNHf7mwLyoT1INY4tmrI7sN7guP8Po8qFDUwiP945c-G8=\" rel=\"nofollow\" target=\"_blank\">www.nkartatx.com<\/a>.<\/p>\n<p>\n        <strong>Nkarta Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Nadir Mahmood<br \/>Nkarta, Inc.<br \/>nmahmood@nkartatx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWZiNzlkNmUtNGRhZi00MzNmLTk1Y2QtOGNlY2I4MzM1NmQwLTExMDk5NjAtMjAyNS0xMC0yMi1lbg==\/tiny\/Nkarta-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company\u2019s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898925","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company\u2019s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates &hellip; Continue reading &quot;Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T14:10:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting\",\"datePublished\":\"2025-10-22T14:10:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/\"},\"wordCount\":414,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/\",\"name\":\"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\",\"datePublished\":\"2025-10-22T14:10:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company\u2019s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates &hellip; Continue reading \"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T14:10:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting","datePublished":"2025-10-22T14:10:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/"},"wordCount":414,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/","name":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=","datePublished":"2025-10-22T14:10:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE0OSM3MjA5MTkzIzIwOTgzODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898925"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}